Expert Opinion on Therapeutic Patents
Volume 33, 2023 - Issue 7-8
Review
Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020–2022 patent update
, , 
, , , & show all
Carmen Wänglerc Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germanyhttps://orcid.org/0000-0003-1161-8669View further author information
https://orcid.org/0000-0003-1161-8669View further author information, Björn Wänglerd Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germanyhttps://orcid.org/0000-0003-3877-5576View further author information
https://orcid.org/0000-0003-3877-5576View further author information, , Ralf Schirrmachera Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Canadahttps://orcid.org/0000-0002-7098-3036View further author information
https://orcid.org/0000-0002-7098-3036View further author information & Justin J. Baileye Life Sciences Division, TRIUMF, Vancouver, CanadaCorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-8280-5712View further author information
https://orcid.org/0000-0002-8280-5712View further author information show all